Biote

Biote EBIT CAGR 5Y

The EBIT CAGR (5 Year) of Biote (BTMD) as of Nov 5, 2026 is 7.91 %. In the previous year, EBIT CAGR (5 Year) was 7.91 % — a change of 0.00% (lower).

EBIT CAGR 5Y

7.91 %

YoY

0.00%

Last updated:

EBIT CAGR (5 Year) of Biote is 2025 7.91 % . EBIT CAGR (5 Year) of Biote was 2024 7.91 % . It decreases by 0.00% lower compared to the previous year.

The Biote EBIT CAGR 5Y history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT CAGR 5Y
Date
EBIT CAGR 5Y
Jan 1, 2019
7.91 USD
Jan 1, 2020
7.91 USD
Jan 1, 2021
7.91 USD
Jan 1, 2022
7.91 USD
Jan 1, 2023
7.91 USD
Jan 1, 2024
7.91 USD
Jan 1, 2025
7.91 USD
The Biote EBIT CAGR 5Y history
YEAREBIT CAGR 5YYoY
7.91 %0.00%
7.91 %0.00%
7.91 %0.00%
7.91 %0.00%
7.91 %0.00%
7.91 %0.00%
7.91 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biote Stock analysis

What does Biote do? biote Corp. generates revenue through its Biote Method platform, which offers certified practitioners comprehensive tools for hormone optimization. The platform includes education, training, certification, practice management software, inventory management software, and marketing support. Biote also sells a branded line of dietary supplements directly to practitioners and patients. The company's primary customers are Biote-certified practitioners who use the platform to build and manage hormone optimization programs, while the dietary supplements target patients seeking complementary wellness solutions. The Biote Method's proprietary clinical decision support (CDS) system helps physicians personalize patient dosing, enhancing the value proposition for practitioners. By providing end-to-end solutions—from certification to software tools—biote Corp. creates recurring revenue streams through ongoing platform usage and product sales. The company's focus on hormone replacement therapy (HRT) products and practitioner support positions it within the specialized healthcare market segment for bio-identical hormone therapy. biote Corp. differentiates itself through its woman-led structure and comprehensive approach to hormone optimization. The firm's revenue model relies on both service-based offerings for practitioners and direct sales of branded supplements. This dual approach ensures consistent income from certified practitioners who depend on the platform for practice management and from patients purchasing the supplement line as part of their wellness regimen. Biote is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biote stock

EBIT CAGR (5 Year) of Biote is 7.91 % in 2025.

On Eulerpool you can find the complete historical development of EBIT CAGR (5 Year) Biote since 2006 – with annual values, charts, and detailed analysis.

The 5-year EBIT CAGR shows the compound annual growth rate of EBIT over the past five years.

To evaluate EBIT CAGR (5 Year)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT CAGR (5 Year).

EBIT CAGR (5 Year)'s is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT CAGR (5 Year)'s Biote historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Biote

All Key Metrics — Biote